On December 19, 2022 EORTC and ALLIANCE reported that the target accrual in A031102/EORTC1407 TIGER study has been reached (Press release, EORTC, DEC 19, 2022, View Source [SID1234625398]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A031102/EORTC 1407 (TIGER) is an international phase III trial that seeks to establish the standard of care for second-line (also called initial salvage) chemotherapy in patients with advanced germ cell tumors (GCT). TIGER compares initial salvage conventional-dose chemotherapy (CDCT) with the TIP regimen vs. high-dose chemotherapy and autologous stem cell transplant (HDCT/ASCT) with the TI-CE regimen with a primary endpoint of overall survival. The completion of patient recruitment is a major milestone for this groundbreaking trial.
EORTC would like to thank the collaborating groups who have supported this trial, including our funding partner @MOVEMBER. Without them, this trial would not have been possible in Europe.
"The TIGER trial is significant because collaboration between the Alliance/NCI and EORTC demonstrates that it is possible to conduct investigator-initiated randomized clinical trials in rare malignancies through the cooperative group mechanism in the absence of pharmaceutical company support. To our knowledge, TIGER is the first transatlantic cooperative group-led randomized trial conducted in GCT. This landmark study was open at 63 enters within 13 countries across 3 continents (North America, Europe, and Australia/New Zealand), and has helped pave the way for additional CTEP/NCI-led trials in other rare malignancies via collaboration with EORTC or other international partners."